HHS rolled out a new $500 million initiative to develop universal vaccines for 'pandemic-prone' viruses such as influenza and ...

While Pfizer recently pulled the plug on its most advanced obesity candidate, Amgen has moved its own key weight loss play ...

Kro­nos Bio, the drug de­vel­op­er long led by Gilead vet­er­an Nor­bert Bischof­berg­er, is call­ing it quits. The biotech ...

HHS Secretary Robert F. Kennedy Jr. claimed that moving forward, all new vaccines will need to be tested in ...

Moderna tried to assuage investors Thursday that enhanced scrutiny of its vaccines in the US wouldn’t hamper its progress.

Eli Lilly CEO David Ricks continued his pushback against the Trump administration's plan to put tariffs on pharmaceutical ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

Moderna is expanding a cost control program as it seeks to break even in the coming years, despite challenges for vaccine ...

Icon and Medpace report high R&D project cancellations; Icon sees $659M in Q1 cancellations, cuts guidance; Medpace notes ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

Amicus pays Dimerix $30M upfront for US rights to DMX-200, a late-stage FSGS therapy, with potential milestone payments of ...